Metabolic Fluid Responsiveness in Children
The investigators aim to validate markers of metabolic fluid-responsiveness in children with acute circulatory failure following cardiac surgery. This would allow physicians to identify which patient could benefit the most from fluid expansion, thus avoiding useless and potentially dangerous fluid expansions that could
| Condition(s) | Circulatory Failure / Shock State, Fluid Therapy |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The investigators aim to validate markers of metabolic fluid-responsiveness in children with acute circulatory failure following cardiac surgery. This would allow physicians to identify which patient could benefit the most from fluid expansion, thus avoiding useless and potentially dangerous fluid expansions that could lead to fluid overload. To this end, The investigators will evaluate the diagnostic accuracy of the ratio of central venous to arterial carbon dioxide tension (Pv-aCO2) to arteriovenous oxygen content (CavO2), a simple biological marker of anaerobic metabolism, for the diagnosis of metabolic fluid responsiveness defined as a significant increase in oxygen consumption (VO2) after fluid expansion. |
| Who can participate | Inclusion Criteria: * Age less than or equal to 15 years old * Hospitalization in a pediatric intensive care unit after cardiac surgery * Prescription by the attending physician of a fluid expansion of 10ml/kg * Prescription of arterial and venous blood gas before and after the volume expansion to help manage acute circulatory failure * Patient implanted with a functioning arterial line * Patient implanted with a functioning central venous line in the superior vena cava territory Exclusion Criteria: * Patient less than 37 weeks' corrected gestational age * Hemodynamic instability making the delay necessary for any test dangerous * Supine position contraindicated or deleterious * Impairment of echocardiographic acoustic window or restless patient making ultrasonography impossible * Oppositi |
| Ages | 0 Days to 15 Years |
| Sex | All |
| Lead sponsor | University Hospital, Bordeaux |
| Locations | Bron, France, France; Lille, France, France; Marseille, France, France; Nantes, France, France; Paris, France, France; Pessac, France, France (+2 more sites) |
| Start date | 2025-03-21 |
| NCT ID | NCT07255469 |
| Official listing | https://clinicaltrials.gov/study/NCT07255469 |